-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61

Benzinga·06/22/2026 12:56:24
Listen to the news
Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.